Fresenius Settles With Johnson & Johnson to Market Stelara Alternative
By David Sachs
Pharmaceutical companies Fresenius Kabi and Formycon have reached a settlement with Johnson & Johnson to commercialize a Crohn's Disease drug in Europe and Canada.
Fresenius said Monday that the terms of the settlement for the drug, which mirrors Johnson & Johnson's trademarked Stelara, are confidential. Known as FYB202, the treatment also aids people with plaque psoriasis and ulcerative colitis, and is awaiting approval from regulators.
The settlement follows a similar one with Johnson & Johnson in the U.S. context. Fresenius Kabi and Formycon have had a license agreement in place since last year for marketing the drug after its approval, Fresenius said.
Johnson & Johnson did not immediately respond to a request for comment.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
March 18, 2024 05:51 ET (09:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters
-
CVS Earnings: Weak Medicare Advantage Profits Cut Into 2024 Outlook
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters